Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial

Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.2%
    Check dated 2026-04-17T13:35:05.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The study page content appears unchanged; the screenshots show the same information with only minor formatting or metadata updates.
    Difference
    0.1%
    Check dated 2026-04-10T08:53:57.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The change seems limited to the page's last-update timestamp; core study details, including eligibility criteria, endpoints, and locations, appear unchanged.
    Difference
    0.1%
    Check dated 2026-04-03T05:26:59.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.5.0 is now shown, replacing the previous Revision: v3.4.3.
    Difference
    0.2%
    Check dated 2026-03-19T20:47:20.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.1%
    Check dated 2026-03-12T19:40:55.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    GenSight Biologics is added as sponsor and Magali Taiel, MD is removed as investigator.
    Difference
    0.4%
    Check dated 2026-03-05T17:46:16.000Z thumbnail image

Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.